Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy

Kang Qin, Kaiwen Wang, Shenduo Li, Lingzhi Hong, Priyadharshini Padmakumar, Rinsurongkawong Waree, Shawna M. Hubert, Xiuning Le, Natalie Vokes, Kunal Rai, Ara Vaporciyan, Don L. Gibbons, John V. Heymach, J. Jack Lee, Scott E. Woodman, Caroline Chung, David A. Jaffray, Mehmet Altan, Yanyan Lou, Jianjun Zhang

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy'. Together they form a unique fingerprint.

Medicine & Life Sciences